| Kimberly Kay Blain, MD | |
|
2800 10th Ave N, Billings, MT 59101-0703 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Kimberly Kay Blain |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 2800 10th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174064430 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MED-PHYS-LIC-93604 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Stillwater Billings Clinic | Columbus, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
| Billings Clinic | 6002993516 | 659 |
News Archive
Rural hospitals may not be able to keep their doors open as the coronavirus pandemic saps their cash, their CEOs warn, just as communities most need them.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product. The ANDA is currently under review with FDA.
Today, machine learning, artificial intelligence, and algorithmic advancements made by research scientists and engineers are driving more targeted medical therapies through the power of prediction.
In a recent study of patients with overactive bladder (OAB), a 30 mg extended release formulation of propiverine hydrochloride was at least as effective and safe as a 4 mg extended release formulation of tolterodine tartrate.
› Verified 4 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
Rural hospitals may not be able to keep their doors open as the coronavirus pandemic saps their cash, their CEOs warn, just as communities most need them.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product. The ANDA is currently under review with FDA.
Today, machine learning, artificial intelligence, and algorithmic advancements made by research scientists and engineers are driving more targeted medical therapies through the power of prediction.
In a recent study of patients with overactive bladder (OAB), a 30 mg extended release formulation of propiverine hydrochloride was at least as effective and safe as a 4 mg extended release formulation of tolterodine tartrate.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Kay Blain, MD 2800 10th Ave N, Billings, MT 59101-0703 Ph: (406) 238-2500 | Kimberly Kay Blain, MD 2800 10th Ave N, Billings, MT 59101-0703 Ph: (406) 238-2500 |
News Archive
Rural hospitals may not be able to keep their doors open as the coronavirus pandemic saps their cash, their CEOs warn, just as communities most need them.
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).
Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product. The ANDA is currently under review with FDA.
Today, machine learning, artificial intelligence, and algorithmic advancements made by research scientists and engineers are driving more targeted medical therapies through the power of prediction.
In a recent study of patients with overactive bladder (OAB), a 30 mg extended release formulation of propiverine hydrochloride was at least as effective and safe as a 4 mg extended release formulation of tolterodine tartrate.
› Verified 4 days ago
Albert C. Reynaud, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Chloe Nicole Ekelem, MD Dermatology Medicare: Medicare Enrolled Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Eric L. Maranda, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 178 S 32nd St W Ste 3, Billings, MT 59102 Phone: 406-702-1323 | |
Brooke Elizabeth Yates, MS PAC Dermatology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
James Abbott, MD Dermatology Medicare: Medicare Enrolled Practice Location: 2825 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Diana Norton, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |